A recent study published in Addiction examined polysubstance overdose deaths in the United States during the transition to the fourth wave of the drug overdose crisis. The researchers analyzed national death records from 2010 to 2021 and found an over 50 fold increase in overdose deaths involving both fentanyl and stimulants, with the most substantial …
New Study: 4th Wave Of Opiate Crisis Skyrockets Read More »
Despite a significant decline in prescription opiate prescribing, opioid deaths are still rising due to synthetic fentanyl. This article discusses the overlooked role of the southern border in this issue.
Researchers from Boston College, Boston University, and Giner Labs have developed a groundbreaking penny-sized biosensor using atom-thick graphene. This innovative device, described in ACS Nano, is the first to utilize graphene-based field effect transistors for detecting four different opioids simultaneously in wastewater, addressing a key challenge in understanding opioid usage within communities. When an opioid …
Is Wastewater Sampling The New Dumpster Diving? Read More »
The US Drug Enforcement Administration (DEA) has outlined an eight-hour training requirement on the treatment and management of opioid patients. The Medication Access and Training Expansion Act mandates the training for all DEA-registered providers, with the deadline for completion set for the date of a practitioner’s next scheduled DEA registration submission beginning on June 27. Graduates from medical and dental schools are exempt from the requirement. The training does not have to occur in one session, and courses previously undertaken in accordance with state-mandated continuing education will apply.
This article discusses the recent approval of the first over-the-counter naloxone nasal spray for use in reversing opioid overdoses. The U.S. Food and Drug Administration (FDA) has approved the first over-the-counter (OTC) naloxone nasal spray, Narcan, to help prevent opioid overdoses. The nasal spray is intended for use in adults and adolescents, and the FDA …
The ADA has issued a FAQ (frequently asked questions) providing additional information regarding the 2022 Omnibus Bill with provisions for the MATE Act – which included a controlled substance education requirement for continuing DEA registration. The FAQ suggests further information and guidance will be forthcoming by the end of March. The Act contains exclusions and …
It has come to our attention a little known provision of the federal omnibus bill approved in the waning hours of 2022 included a requirement that could impact your practice if not properly managed. The Medication Access and Training Expansion (MATE) Act, which aims to improve access to medications and expand training for healthcare professionals …
A recent CDC analysis shows that antihistamines, particularly first-generation H1 subtype antihistamines like diphenhydramine, play a role in drug overdoses. Opioids were involved in most cases, and naloxone may not work with antihistamines. Continual monitoring is important.
Healthcare professionals have been alerted by the FDA to the dangers of patients being exposed to xylazine, a veterinary sedative, in illicit drugs. The FDA advises healthcare professionals to report any adverse events related to xylazine.
Fentanyl is now the leading cause of overdose deaths among young people, with a nearly 500% increase in deaths among those aged 25 and under. Learn more.
Main Menu
User Menu
